FMTX News and Press, Forma Therapeutics Holdings Inc. From 01/07/21

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that Selwyn M. Vickers, M.D., F.A.C.S., has been elected to serve on the company’s board of directors. This press...

Forma Therapeutics ([[FMTX]] -7.8%) closed an underwritten public offering of ~6.1M common stock, including the exercise in full of underwriters' over-allotment of an additional 795K shares, at a public offering price of $45.25 per share.Gross proceeds of ~$275.8M and ...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the closing of an underwritten public offering of 6,095,000 shares of its common stock, including the exercise in full by the un...

Four IPOs and one SPAC are scheduled to raise $1.7 billion in the week ahead. Street research is expected for six companies. Lock-up periods will be expiring for eight companies. For further details see: U.S. IPO Weekly Recap: Airbnb And DoorDash Make Their Public Debuts...

Forma Therapeutics (FMTX) has priced its public offering of 5.3M common shares at $45.25/share, for expected gross proceeds of ~$239.8M.Underwriters' over-aalotment is an additional 795K shares.Closing date is December 15. For further details see: Forma Therapeutics prices equity offeri...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock at a public offering price of $45.25 per ...

The 62nd ASH Annual Meeting and Exposition held virtually this year from December 5-8, 2020, has highlighted promising experimental therapies in biotech, enabling their developers to fortify their balance sheets through secondary offers as investors pore through the trial data.Since November ...

Forma Therapeutics (FMTX) has launched a proposed public offering of 4.6M shares. Underwriters have an option to purchase up to 690k additional shares.Price is yet to be determined. For further details see: Forma Therapeutics initiates equity offering of 4.6M shares

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it has launched a proposed public offering of 4,600,000 shares of its common stock. All of the shares of common stock i...

Forma Therapeutics ([[FMTX]] +2.9%) gains while competitor Agios Pharmaceuticals slides, after the pair presented updated data for their sickle cell disease candidates at the annual ASH meeting.FMTX’s FT-4202 data suggest a best-in-class asset as hemoglobin response rate was higher tha...